A detailed history of Janus Henderson Group PLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Janus Henderson Group PLC holds 1,009,094 shares of LGND stock, worth $115 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,009,094
Previous 1,008,733 0.04%
Holding current value
$115 Million
Previous $85 Million 18.92%
% of portfolio
0.05%
Previous 0.05%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$82.7 - $110.11 $29,854 - $39,749
361 Added 0.04%
1,009,094 $101 Million
Q2 2024

Aug 14, 2024

BUY
$68.53 - $87.91 $17,543 - $22,504
256 Added 0.03%
1,008,733 $85 Million
Q1 2024

May 15, 2024

SELL
$68.64 - $89.2 $23 Million - $29.9 Million
-334,677 Reduced 24.92%
1,008,477 $73.7 Million
Q4 2023

Feb 14, 2024

BUY
$49.57 - $72.63 $63,499 - $93,039
1,281 Added 0.1%
1,343,154 $95.9 Million
Q3 2023

Nov 14, 2023

SELL
$58.86 - $72.67 $157,862 - $194,900
-2,682 Reduced 0.2%
1,341,873 $80.4 Million
Q2 2023

Aug 14, 2023

BUY
$69.53 - $79.33 $5.89 Million - $6.72 Million
84,670 Added 6.72%
1,344,555 $96.9 Million
Q1 2023

May 15, 2023

BUY
$65.67 - $77.08 $302,870 - $355,492
4,612 Added 0.37%
1,259,885 $92.7 Million
Q4 2022

Feb 14, 2023

SELL
$61.72 - $96.74 $435,743 - $682,984
-7,060 Reduced 0.56%
1,255,273 $83.9 Million
Q3 2022

Nov 14, 2022

SELL
$0.01 - $107.56 $1,271 - $13.7 Million
-127,155 Reduced 9.15%
1,262,333 $109 Million
Q2 2022

Aug 15, 2022

BUY
$74.52 - $117.06 $31,372 - $49,282
421 Added 0.03%
1,389,488 $124 Million
Q1 2022

May 16, 2022

SELL
$94.99 - $151.56 $4.94 Million - $7.88 Million
-52,018 Reduced 3.61%
1,389,067 $156 Million
Q4 2021

Feb 14, 2022

SELL
$127.69 - $165.85 $2.79 Million - $3.62 Million
-21,815 Reduced 1.49%
1,441,085 $223 Million
Q3 2021

Nov 16, 2021

BUY
$102.33 - $144.73 $1.91 Million - $2.7 Million
18,679 Added 1.29%
1,462,900 $204 Million
Q2 2021

Aug 16, 2021

BUY
$113.03 - $155.64 $21.1 Million - $29 Million
186,424 Added 14.82%
1,444,221 $189 Million
Q1 2021

May 17, 2021

SELL
$99.52 - $215.83 $35.3 Million - $76.5 Million
-354,572 Reduced 21.99%
1,257,797 $192 Million
Q4 2020

Feb 16, 2021

BUY
$80.55 - $106.05 $509,720 - $671,084
6,328 Added 0.39%
1,612,369 $160 Million
Q3 2020

Nov 16, 2020

BUY
$89.56 - $126.72 $95,560 - $135,210
1,067 Added 0.07%
1,606,041 $153 Million
Q2 2020

Aug 14, 2020

BUY
$68.28 - $123.65 $914,405 - $1.66 Million
13,392 Added 0.84%
1,604,974 $180 Million
Q1 2020

May 14, 2020

SELL
$63.37 - $107.88 $14.3 Million - $24.4 Million
-225,892 Reduced 12.43%
1,591,582 $116 Million
Q4 2019

Feb 18, 2020

BUY
$96.94 - $113.59 $24.4 Million - $28.6 Million
251,452 Added 16.06%
1,817,474 $190 Million
Q3 2019

Nov 14, 2019

BUY
$86.25 - $120.16 $2.01 Million - $2.81 Million
23,352 Added 1.51%
1,566,022 $156 Million
Q2 2019

Jul 31, 2019

BUY
$107.38 - $129.34 $16.9 Million - $20.4 Million
157,604 Added 11.38%
1,542,670 $176 Million
Q1 2019

Apr 30, 2019

BUY
$105.93 - $142.47 $42 Million - $56.4 Million
396,166 Added 40.06%
1,385,066 $174 Million
Q4 2018

Feb 06, 2019

BUY
$128.36 - $272.13 $11.4 Million - $24.2 Million
88,813 Added 9.87%
988,900 $134 Million
Q3 2018

Nov 09, 2018

SELL
$211.18 - $274.49 $5.7 Million - $7.42 Million
-27,014 Reduced 2.91%
900,087 $247 Million
Q2 2018

Aug 10, 2018

BUY
$150.77 - $207.98 $8.29 Million - $11.4 Million
54,990 Added 6.31%
927,101 $192 Million
Q1 2018

May 14, 2018

SELL
$138.63 - $182.62 $5.86 Million - $7.72 Million
-42,274 Reduced 4.62%
872,111 $144 Million
Q4 2017

Feb 09, 2018

BUY
$128.36 - $147.04 $20.5 Million - $23.5 Million
159,693 Added 21.16%
914,385 $125 Million
Q3 2017

Nov 14, 2017

BUY
$120.91 - $137.94 $19.2 Million - $22 Million
159,201 Added 26.73%
754,692 $0
Q2 2017

Aug 17, 2017

BUY
N/A
595,491
595,491 $72.3 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.92B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.